Search results
-
Roche walks away from Hookipa’s KRAS immunotherapy
… immunotherapy HPV16+ HNSCC Ph1/2 1L + Keytruda ESMO 2023: 42% ORR (8/19 pts); more data due H1 2024; …
- 01/30/2024 - 13:42 -
Trodelvy throws second-line lung cancer another curveball
… and a secondary endpoint in Evoke-01. Source: ESMO 2023 & Gilead press release. Trial …
- 01/23/2024 - 15:04 -
ASCO-GI – Jacobio’s KRAS looks competitive in pancreatic
… cancer with its multi-RAS inhibitor RMC-6236 at ESMO 2023; however, this study excluded G12C mutants. …
- 01/18/2024 - 14:56 -
ASCO-GU preview: showdown for Exelixis
… in neuroendocrine prostate cancer 121 Had data at ESMO 2023; company sold to Merck & Co Keynote-564 …
- 01/25/2024 - 10:22 -
Cell cycle niche seeks clinical validation
… +/- platinum chemo, started Aug 2023; preclinical data at ESMO 2023 AZD8421 AstraZeneca Cycad-1 trial …
- 01/12/2024 - 17:23 -
J&J deal cements Ambrx’s transformation
… cohorts 4-8 the confirmed ORR was 22%. Source: ESMO 2023. Any lingering doubts now become …
- 01/10/2024 - 14:31 -
Merck’s latest move is in bispecifics
… toxicity. In a phase 1/2 study presented at ESMO 2023 HPN328 produced a confirmed response rate of 32% … house Ph1 +/- Keytruda in solid tumours ; data at ESMO 2023 Not yet given Source: Mizuho note, …
- 06/19/2024 - 16:48 -
ASCO-GI preview: notable late-breakers
… 604 KRAS G12C inhibitor with solid tumour data at ESMO 2023 Defiance Leap Therapeutics DKN-01 + …
- 01/09/2024 - 11:43 -
Merck KGaA takes a punt on Inspirna’s novel approach
… with ompenaclid in second-line CRC Source: ESMO 2023. By way of benchmarks, Folfiri chemo …
- 01/05/2024 - 13:36 -
Bristol makes its radiopharma move
… data are expected late 2025 or early 2026 . At ESMO 2023, phase 1b data from that study found a 29% overall …
- 01/03/2024 - 17:27
